Screener
Whitehawk Therapeutics WHWK EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Whitehawk Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Whitehawk Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212075
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Unrealized loss on investments, net of tax | (135) | (15) |
| Comprehensive (loss) income | (22,329) | 73,001 |
| Net (loss) income per share: | ||
| Basic | $(0.32) | $1.84 |
| Diluted | $(0.32) | $1.83 |
| Weighted average shares outstanding: | ||
| Basic | 69,236,945 | 39,640,826 |
| Diluted | 69,236,945 | 39,932,539 |
Item 1. Financial Statements.
FAQ
- What is Whitehawk Therapeutics's EPS (diluted)?
- Whitehawk Therapeutics (WHWK) reported EPS (diluted) of -$0.32 in Q1 2026.
- How has Whitehawk Therapeutics's EPS (diluted) changed year-over-year?
- Whitehawk Therapeutics's EPS (diluted) decreased by 117.5% year-over-year, from $1.83 to -$0.32.
- What is the long-term trend for Whitehawk Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), Whitehawk Therapeutics's EPS (diluted) has grown at a -67.1% compound annual growth rate (CAGR), from -$12.41 to $0.44.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Whitehawk Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude